A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer

Phase 2 Completed 15 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the effectiveness of LY2875358 in participants with MET diagnostic positive (+), advanced gastric or gastroesophageal junction (GEJ) cancer.

Timeline

Start: 2013-08
Primary completion: 2014-08
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Emibetuzumab	Monoclonal antibody	2000 mg	Intravenous

A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer

Summary

Timeline

Drugs

Indications